| Entry |
|
|---|
| Name |
Droxidopa (JP18/USAN/INN);
Dops (TN);
Northera (TN) |
|---|
| Product |
|
|---|
| Generic |
DROXIDOPA (Ajanta Pharma Limited), DROXIDOPA (Ascend Laboratories), DROXIDOPA (Aurobindo Pharma Limited), DROXIDOPA (Bionpharma), DROXIDOPA (Cadila Healthcare Limited), DROXIDOPA (Camber Pharmaceuticals), DROXIDOPA (Hikma Pharmaceuticals USA), DROXIDOPA (Lupin Pharmaceuticals), DROXIDOPA (MSN LABORATORIES PRIVATE LIMITED), DROXIDOPA (Novadoz Pharmaceuticals LLC), DROXIDOPA (ScieGen Pharmaceuticals), DROXIDOPA (Slate Run Pharmaceuticals), DROXIDOPA (Sun Pharmaceutical Industries), DROXIDOPA (Tris Pharma), DROXIDOPA (Upsher-Smith Laboratories), DROXIDOPA (Zydus Pharmaceuticals (USA)) |
|---|
| Formula |
C9H11NO5
|
|---|
| Exact mass |
213.0637
|
|---|
| Mol weight |
213.1873
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Neuropsychiatric agent
DG01967 Antiparkinson agent
|
|---|
| Remark |
| Therapeutic category: | 1169 |
|
|---|
| Efficacy |
Antiparkinsonian, Replenisher (noradrenalin) |
|---|
| Disease |
Parkinson disease [DS: H00057] Multiple system atrophy [DS: H01614] Dopamine beta-hydroxylase deficiency [DS: H01005] |
|---|
| Comment |
precursor of Norepinephrine [DR: D00076]
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04080 | Neuroactive ligand-receptor interaction |
| hsa04261 | Adrenergic signaling in cardiomyocytes |
|
|---|
| Interaction |
|
|---|
| Structure map |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
C CARDIOVASCULAR SYSTEM
C01 CARDIAC THERAPY
C01C CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES
C01CA Adrenergic and dopaminergic agents
C01CA27 Droxidopa
D01277 Droxidopa (JP18/USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Cardiovascular Agents
Alpha-adrenergic Agonists
Droxidopa
D01277 Droxidopa (JP18/USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
1 Agents affecting nervous system and sensory organs
11 Agents affecting central nervous system
116 Antiparkinsonian agents
1169 Others
D01277 Droxidopa (JP18/USAN/INN)
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Adrenaline
ADRA1
D01277 Droxidopa (JP18/USAN/INN) <JP/US>
ADRA2
D01277 Droxidopa (JP18/USAN/INN) <JP/US>
ADRB
D01277 Droxidopa (JP18/USAN/INN) <JP/US>
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
Chemicals
D01277 Droxidopa
D01277 Droxidopa capsules
D01277 Droxidopa fine granules
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D01277
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D01277
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 15
1 C8y C 5.1800 -5.1100
2 C8y C 5.1800 -6.5100
3 C8x C 6.4400 -7.2100
4 C8x C 7.6300 -6.5100
5 C8y C 7.6300 -5.1100
6 C8x C 6.4400 -4.4100
7 O1a O 3.9900 -7.2100
8 C1c C 8.8200 -4.4100
9 C1c C 10.0100 -5.1100
10 C6a C 11.2700 -4.4100
11 O6a O 12.4600 -5.1100
12 O6a O 11.2700 -3.0100
13 O1a O 8.8200 -3.0100
14 N1a N 10.0100 -6.5100
15 O1a O 3.9734 -4.4000
BOND 15
1 1 2 2
2 2 3 1
3 5 8 1
4 3 4 2
5 8 9 1
6 4 5 1
7 9 10 1
8 5 6 2
9 10 11 1
10 6 1 1
11 10 12 2
12 8 13 1 #Up
13 2 7 1
14 9 14 1 #Up
15 1 15 1
|
|---|
